Pfizer looks to right sterile injectable woes with modernized manufacturing

Pfizer has spent years on the receiving end of the FDA's wrath for continued manufacturing issues surrounding the drugmaker's 2015 buyout of Hospira. Now, after a year of trying to right the ship with that portfolio, Pfizer may have found its footing, with supply on the upswing.